HK Stock Market Move | GENSCRIPT BIO (01548) rose over 8% as AIDD demand accelerates. Institutions indicate that performance exceeds expectations.

GENSCRIPT BIO (01548) rose over 8%, and as of the publication, it is up 5.6%, priced at HKD 27.54, with a transaction volume of HKD 416 million. In terms of news, GENSCRIPT BIO announced that its revenue for the first half of the year was approximately USD 404 million, a year-on-year increase of 27.3%; the net loss attributable to shareholders was USD 129 million, a year-on-year reduction; the adjusted net profit was around USD 62.5 million, a year-on-year increase of 203.3%. CICC highlighted that GENSCRIPT's performance exceeded expectations, mainly due to strong growth in its AIDD catalyst life sciences business and improved operational efficiency. Notably, GENSCRIPT BIO updated its guidance for 2026: Life Sciences: revenue growth of 25-30% for the year, adjusted gross margin increased to 55%+, and adjusted operating margin increased to 25%+; revenue from AIDD-related orders is expected to maintain a doubling growth trend in the future. CDMO: FFS revenue (excluding licensing revenue) growth of 25-30%; this business segment is expected to achieve EBITDA breakeven by 2027. Synthetic Biology: revenue growth of 8-10%, adjusted gross margin increased to 43%+.